home.social

#sny — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #sny, aggregated by home.social.

  1. Sanofi gets FDA approval for Sarclisa on-body injector | SNY SEC Filing

    “The introduction of Sarclisa Escena with the innovative CirCLIQ on-body injector represents a significant advancement in multiple myeloma…
    #France #FR #Europe #EU #Sanofi #CirCLIQ #EnableInjections #enFuse #FDAapproval #multiplemyeloma #on-bodyinjector #phase3IRAKLIA #SarclisaEscena #SNY
    europesays.com/france/52785/

  2. Sanofi posts positive Nexviazyme phase 3 IOPD data | SNY SEC Filing

    About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling…
    #France #FR #Europe #EU #Sanofi #Baby-COMET #biopharma #enzymereplacementtherapy #infantile-onsetPompe #labelextension #Nexviazyme #phase3trial #Pompedisease #SNY
    europesays.com/france/47935/

  3. Sanofi wins key EU, Japan drug approvals and new R&D head | SNY SEC Filing

    About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling…
    #France #FR #Europe #EU #Sanofi #Cenrifki #drugapprovals #Form6-K #immunethrombocytopenia #multiplemyeloma #multiplesclerosis #PauloFontoura #Sarclisa #SNY #Wayrilz
    europesays.com/france/40606/

  4. Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma

    Sanofi SNY announced that the European Commission (EC) has approved the subcutaneous (under the skin or SC) formulation…
    #France #FR #Europe #EU #Sanofi #futures #indexmarketquote #indexmarketquotes #indexmarketsymbol #indexmarketsymbols #indices #Sanofi-AventisS.A.ADR #SNY #TheGlobeandMail
    europesays.com/france/32739/

  5. Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?

    Sanofi’s SNY stock has declined 5.9% in the past three months despite reporting double-digit sales and earnings growth…
    #France #FR #Europe #EU #Sanofi #futures #indexmarketquote #indexmarketquotes #indexmarketsymbol #indexmarketsymbols #indices #Sanofi-AventisS.A.ADR #SNY #TheGlobeandMail
    europesays.com/france/30783/

  6. GSK Bets on Specialty Medicines to Drive Long-Term Revenue Growth

    GSK plc’s GSK Specialty Medicines business has become the company’s primary growth engine, accounting for more than 40%…
    #EuropeSays #Britain #Europe #EU #GSK #futures #indexmarketquote #indexmarketquotes #indexmarketsymbol #indexmarketsymbols #indices #Sanofi-AventisS.A.ADR #SNY #TheGlobeandMail
    europesays.com/britain/55434/